EVIDENCE REVIEW

1847  Pancreatic adenocarcinoma: Beyond first line, where are we?

Cherri S, Noventa S, Zaniboni A

REVIEW

1864  Non-alcoholic fatty liver and chronic kidney disease: Retrospect, introspect, and prospect

Heda R, Yazawa M, Shi M, Bhaskaran M, Aloor FZ, Thuluvath PJ, Satapathy SK

1883  Repurposing metformin for the treatment of gastrointestinal cancer

Cunha Júnior AD, Bragagnoli AC, Costa FO, Carvalheira JBC

1905  Mesenchymal stromal cell secretome in liver failure: Perspectives on COVID-19 infection treatment


MINIREVIEWS

1920  Artificial intelligence applications in inflammatory bowel disease: Emerging technologies and future directions

Gubatan J, Levitte S, Patel A, Balabanis T, Wei MT, Sinha SR

1936  Post-pancreatitis diabetes mellitus and excess intra-pancreatic fat deposition as harbingers of pancreatic cancer

Petrov MS

1943  BRCA mutated pancreatic cancer: A change is coming

Rosen MN, Goodwin RA, Vickers MM

1959  Metabolic and cardiovascular complications after virological cure in hepatitis C: What awaits beyond

Shengir M, Elgara M, Sebastiani G

ORIGINAL ARTICLE

Basic Study

1973  S100 calcium binding protein A6 and associated long noncoding ribonucleic acids as biomarkers in the diagnosis and staging of primary biliary cholangitis

Dong XH, Dai D, Yang ZD, Yu XO, Li H, Kang H

1993  Long non-coding RNA TP73-AS1 promotes pancreatic cancer growth and metastasis through miRNA-128-3p/GOLM1 axis

Wang B, Sun X, Huang KJ, Zhou LS, Qiu ZJ
Contents

Retrospective Study

2015 Prediction of microvascular invasion in solitary hepatocellular carcinoma ≤ 5 cm based on computed tomography radiomics
Liu P, Tan XZ, Zhang T, Gu QB, Mao XH, Li YC, He YQ

2025 Hepatocellular carcinoma progression in hepatitis B virus-related cirrhosis patients receiving nucleoside (acid) analogs therapy: A retrospective cross-sectional study
Yang DH, Wang WP, Zhang Q, Pan HY, Huang YC, Zhang JJ

Observational Study

2039 Hypophosphatemia after high-dose intravenous iron treatment in patients with inflammatory bowel disease: Mechanisms and possible clinical impact
Detlie TE, Lindstrøm JC, Jahnsen ME, Finnes E, Zoller H, Moum B, Jahnsen J
ABOUT COVER
Editorial Board Member of World Journal of Gastroenterology, Abhinav Vasudevan, Bachelor of Medicine, MPH, PhD, FRACP, Advanced Inflammatory Bowel Disease Fellow, Mayo Clinic, 200 1st Street SW, Rochester, MN 55902, United States. vasudevan.abhinav@mayo.edu

AIMS AND SCOPE
The primary aim of World Journal of Gastroenterology (WJG, World J Gastroenterol) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING
The WJG is now indexed in Current Contents®/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports®, Index Medicus, MEDLINE, PubMed, PubMed Central, and Scopus. The 2020 edition of Journal Citation Report® cites the 2019 impact factor (IF) for WJG as 3.665; IF without journal self cites: 3.534; 5-year IF: 4.048; Ranking: 35 among 88 journals in gastroenterology and hepatology; and Quartile category: Q2. The WJG’s CiteScore for 2019 is 7.1 and Scopus CiteScore rank 2019: Gastroenterology is 17/137.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Yu-Jie Ma; Production Department Director: Xiang Li; Editorial Office Director: Ze-Mao Gong.

NAME OF JOURNAL
World Journal of Gastroenterology

ISSN
ISSN 1007-9327 (print) ISSN 2219-2840 (online)

LAUNCH DATE
October 1, 1995

FREQUENCY
Weekly

EDITORS-IN-CHIEF
Andrzej S Tarnawski, Subrata Ghosh

EDITORIAL BOARD MEMBERS
https://www.wjgnet.com/1007-9327/editorialboard.htm

PUBLICATION DATE
May 7, 2021

COPYRIGHT
© 2021 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/GerInfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS
https://www.wjgnet.com/bpg/gerinfo/288

PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/gerinfo/208

ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/gerinfo/239

ONLINE SUBMISSION
https://www.f6publishing.com
Metabolic and cardiovascular complications after virological cure in hepatitis C: What awaits beyond

Mohamed Shengir, Mohamed Elgara, Giada Sebastiani

Abstract

The association between chronic hepatitis C (CHC) infection and extrahepatic manifestations (EHMs), particularly cardiometabolic diseases, has been extensively examined. However, there has still been insufficient evaluation for these EHMs after virological cure. Several multidirectional mechanisms have been proposed explaining the ability of hepatitis C virus (HCV) developing EHMs, cardiometabolic ones, as well as the effect of antiviral therapy to resolve these EHMs. Data on these manifestations after achieving sustained virologic response (SVR) are still conflicting. However, current evidence suggests that reversal of hepatic steatosis and its coexistent hypcholesterolemia after successful viral eradication led to unfavorable lipid profile, which increases cardiovascular disease (CVD) risk. Additionally, most observations showed that metabolic alterations, such as insulin resistance and diabetes mellitus (DM), undergo some degree of reduction after viral clearance. These changes seem HCV-genotype dependent. Interferon-based antiviral therapy and direct acting antiviral drugs were shown to minimize incidence of DM. Large epidemiological studies that investigated the effect of SVR on CVD showed great discrepancies in terms of results, with predominant findings indicating that CVD events decreased in patients with SVR compared to non-responders or untreated ones. In this review, we present a summary of the current knowledge regarding extrahepatic sequelae of CHC following SVR, which may have an impact on healthcare providers’ clinical practice.

Key Words: Chronic hepatitis C; Sustained virologic response; Hepatic steatosis; Diabetes mellitus; Cardiovascular disease
accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/License/s/by-nc/4.0/

Manuscript source: Invited manuscript

Specialty type: Gastroenterology and hepatology

Country/Territory of origin: Canada

Peer-review report’s scientific quality classification
Grade A (Excellent): A
Grade B (Very good): 0
Grade C (Good): 0
Grade D (Fair): 0
Grade E (Poor): 0

Received: January 25, 2021
Peer-review started: January 25, 2021
First decision: February 27, 2021
Revised: March 6, 2021
Accepted: April 12, 2021
Article in press: April 12, 2021
Published online: May 7, 2021

P-Reviewer: Masaki N
S-Editor: Fan JR
L-Editor: A
P-Editor: Liu JH

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: The implementation of direct acting antiviral drugs has dramatically changed the landscape of hepatitis C virus (HCV) treatment, with over 95% of patients achieving sustained virologic response (SVR). Although consistent evidence demonstrated better outcomes for both hepatic and extrahepatic complications after viral clearance, data on cardiometabolic manifestation showed inconsistent results. In this review, we are shading light on the latest findings about cardiometabolic extrahepatic manifestations post-SVR. These updates may guide clinicians engaged in HCV care to integrate in their management post-viral eradication risks and subsequent long-term care.

DOI: https://dx.doi.org/10.3748/wjg.v27.i17.1959

INTRODUCTION

Chronic hepatitis C (CHC) infection caused by hepatitis C virus (HCV) is associated with substantial morbidity and mortality globally, affecting approximately 2.5% individuals (equivalent to 177.5 million) worldwide[1]. It is currently one of the leading etiologies for hepatocellular carcinoma (HCC) and decompensated cirrhosis requiring liver transplantation in Western countries[2,3]. The primary goal of treatment is to achieve the cure of the infection or sustained virologic response (SVR), defined as undetectable HCV RNA in the serum 12 or 24 wk after the end of treatment[4,5]. Since the introduction of first-generation direct acting antiviral agents (DAAs), boceprevir and telaprevir, in 2011, there has been a rapidly expanding population of CHC patients achieving SVR[6]. Viral eradication has been associated with marked reduction in the risk of end-stage liver disease, need for liver transplantation, and decrease in both liver-related and overall mortality[7].

Although HCV is a hepatotropic virus, for two decades several studies described the association between HCV and a heterogeneous array of extrahepatic manifestations (EHMs)[8-10] (Figure 1). Yet, the mechanism by which the virus evokes the systemic diseases remain to be elucidated. Endocrine-metabolic alterations, which are most frequently found in CHC patients, are thought to be caused by direct and indirect effects of disturbing host lipid and glucose metabolism[11,12], as well as alteration in adipocytokines released from adipose tissue[13,14]. Likewise, CHC infection has also been identified as an independent predictor for cardiovascular events such as carotid artery atherosclerosis, stroke, myocardial ischemia and heart failure, all of which are linked with poor outcomes[12]. Nevertheless, the impact on cardiovascular disease (CVD) is not fully established[15]. In clinical settings, the prognosis of CHC is not only depending on liver-related outcomes but also on extrahepatic sequelae.

Recently, much attention is drawn toward EHMs that occur following viral cure. Nonetheless, whether the development of such manifestations is a long-term consequence of the viral infection itself or an effect of HCV medications remains unknown. In this context, various reports have shown ample evidence for high prevalence of CVD and metabolic alterations such as dyslipidemia, hepatic steatosis, insulin resistance (IR), obesity and diabetes mellitus (DM)[16-19] (Table 1). While the impact of CHC infection on liver-related outcomes pre- and post-treatment has been well studied, extrahepatic sequelae, especially in post-SVR setting, are less well known. This review article highlights the current knowledge regarding the effect of SVR on EHMs.
## Table 1 Summary of studies investigated cardiometabolic manifestations of chronic hepatitis C after viral cure

<table>
<thead>
<tr>
<th>Ref.</th>
<th>Antiviral regimen</th>
<th>The studied HCV-associated cardiometabolic manifestations</th>
<th>Post SVR outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fernández-Rodríguez et al[28], 2006</td>
<td>NA&lt;sup&gt;1&lt;/sup&gt;</td>
<td>Lipid disturbances, Hepatic steatosis</td>
<td>Hypercholesterolemia in patients with genotype 3 regardless of the response</td>
</tr>
<tr>
<td>Giordanino et al[71], 2008</td>
<td>IFN monotherapy or Peg-IFN + RBV (24-48 wk)</td>
<td>Glucose abnormalities (IFG or DM)</td>
<td>Decrease in steatosis</td>
</tr>
<tr>
<td>Arase et al[70], 2009</td>
<td>IFN monotherapy or IFN + RBV&lt;sup&gt;1&lt;/sup&gt;</td>
<td>DM</td>
<td>Decreased incidence of DM in sustained responders. However, its development is associated with advanced liver disease</td>
</tr>
<tr>
<td>Corey et al[68], 2009</td>
<td>NA&lt;sup&gt;1&lt;/sup&gt;</td>
<td>Lipid abnormalities</td>
<td>Increased LDL and total cholesterol from baseline compared to non-responders</td>
</tr>
<tr>
<td>Conjeevaram et al[67], 2011</td>
<td>Peg-IFN + RBV (24-48 wk)</td>
<td>IR</td>
<td>Increased CVD risk profile</td>
</tr>
<tr>
<td>Kuo et al[27], 2011</td>
<td>Peg-IFN + RBV (24 wk)</td>
<td>Change in serum lipid</td>
<td>Total cholesterol and triglycerides levels significantly increased</td>
</tr>
<tr>
<td>Aghemo et al[68], 2012</td>
<td>Peg-IFN + RBV&lt;sup&gt;2&lt;/sup&gt;</td>
<td>IR in non-diabetic CHC patients</td>
<td>Baseline and posttreatment HOMA-IR values were similar in SVR patients</td>
</tr>
<tr>
<td>Clark et al[25], 2012</td>
<td>Albinterferon α-2b + RBV</td>
<td>Lipid abnormalities in genotypes 2,3</td>
<td>Hypercholesterolemia</td>
</tr>
<tr>
<td>Thompson et al[66], 2012</td>
<td>Albinterferon α-2b vs Peg-IFN + RBV (24-48 wk)</td>
<td>IR in genotypes 1,2,3</td>
<td>Reduced IR in genotype 1 responders</td>
</tr>
<tr>
<td>Chang et al[29], 2014</td>
<td>Peg-IFN + RBV (24/48 wk)</td>
<td>Lipids and IR in genotypes 2, 3</td>
<td>Increased total cholesterol and triglycerides in sustained responders</td>
</tr>
<tr>
<td>Hsu et al[88], 2015</td>
<td>Peg-IFN + RBV (16-48 wk)</td>
<td>Acute coronary syndrome and ischemic stroke</td>
<td>Improvement in both studied circulatory outcomes</td>
</tr>
<tr>
<td>Innes et al[89], 2015</td>
<td>NA&lt;sup&gt;1&lt;/sup&gt;</td>
<td>CVD</td>
<td>Reduced hazard and absolute risk for CVD</td>
</tr>
<tr>
<td>Meissner et al[24], 2015</td>
<td>SOF + RBV (24 wk)</td>
<td>Lipid disturbances in genotype 1</td>
<td>Increased LDL level and particle size and decreased triglycerides concentration and VLDL particle size irrespective to treatment response</td>
</tr>
<tr>
<td>Leone et al[72], 2016</td>
<td>IFN-based regimen</td>
<td>DM and CVD</td>
<td>No significant risk reduction in DM and CVD in SVR group as opposed to non SVR</td>
</tr>
<tr>
<td>Yair-Sabag et al[39], 2016</td>
<td>Peg-IFN + RBV (24-48 wk)</td>
<td>IFG and DM, Triglycerides, Hepatic steatosis</td>
<td>Lower IFG and DM, and higher triglycerides in sustained responders</td>
</tr>
<tr>
<td>Chang et al[16], 2017</td>
<td>NA&lt;sup&gt;1&lt;/sup&gt;</td>
<td>Cardiovascular complications</td>
<td>Improvement in hepatic steatosis</td>
</tr>
<tr>
<td>Mahale et al[69], 2018</td>
<td>IFN-based regimen&lt;sup&gt;2&lt;/sup&gt;</td>
<td>DM and CVD</td>
<td>Antiviral therapy associated with lower risk of DM and stroke whereas no significant effect on CVD</td>
</tr>
<tr>
<td>Study</td>
<td>Treatment</td>
<td>Outcome</td>
<td>Comments</td>
</tr>
<tr>
<td>-------</td>
<td>-----------</td>
<td>---------</td>
<td>----------</td>
</tr>
<tr>
<td>Nahon et al [90], 2017</td>
<td>Peg-IFN + RBV (16-48 wk) or combination therapies</td>
<td>CVD</td>
<td>Lower risk of CVD in SVR subjects in comparison to non SVR</td>
</tr>
<tr>
<td>Stine et al [74], 2017</td>
<td>DAA [2,3]</td>
<td>DM in genotypes 1, 2, 3</td>
<td>Glycosylated hemoglobin was not affected in known diabetic patients</td>
</tr>
<tr>
<td>Carvalho et al [11], 2018</td>
<td>SOF + LDV ± RBV (group 1) vs Peg-IFN + RBV (group 2)</td>
<td>Lipid levels. Serum glucose. IR</td>
<td>1/3 of patients required escalation of anti-diabetic therapy during antiviral treatment</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>While total cholesterol increased in both groups, triglycerides levels decreased in group 1 and increased in group 2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>LDL elevated in group 1 and No change in group 2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>No significant variation in serum glucose</td>
</tr>
<tr>
<td>Li et al [73], 2018</td>
<td>DAA [4]</td>
<td>DM</td>
<td>Elevated sdLDL in patients who had dyslipidemia and hepatic steatosis at 24 wk</td>
</tr>
<tr>
<td>Noureddin et al [46], 2018</td>
<td>DAA [3]</td>
<td>Hepatic steatosis and fibrosis</td>
<td>High prevalence of fatty liver</td>
</tr>
<tr>
<td>Li et al [10], 2019</td>
<td>IFN + RBV (48 wk)</td>
<td>Serum glucose level and IR</td>
<td>Reduced glucose level</td>
</tr>
<tr>
<td>Butt et al [87], 2019</td>
<td>IFN + RBV [2,3], DAA [2,3]</td>
<td>CVD</td>
<td>Improved IR</td>
</tr>
<tr>
<td>Abdo et al [75], 2020</td>
<td>SOF + DCV (12-24 wk)</td>
<td>Glycemic status, IR, and lipid profile in CHC patients with DM</td>
<td>Improvement of glycemic state and HOMA-IR</td>
</tr>
<tr>
<td>Graf et al [45], 2020</td>
<td>DAA [3]</td>
<td>IR, lipid perturbations, body weight changes, and hepatic steatosis</td>
<td>Global worsening of lipid profile</td>
</tr>
<tr>
<td>Huang et al [31], 2020</td>
<td>DAA [4]</td>
<td>Lipids and cardiovascular events</td>
<td>Increased total cholesterol and LDL</td>
</tr>
</tbody>
</table>

**DYSLIPIDEMIA**

It has been known that HCV possesses a mutual relationship with host lipids and lipoproteins metabolisms, which the virus uses for multiple key steps in its life cycle[20,21]. HCV circulates as a lipid-rich particle, utilizing lipoprotein cell receptors to gain entry into the hepatocyte[22,23]. Within hepatocytes, it influences three mechanisms in lipid metabolism: it upregulates lipid biosynthesis, impairs...
Figure 1 Hepatic and extrahepatic (cardiometabolic) manifestations associated with hepatitis C virus infection and the effect of sustained virologic response on the cardiometabolic manifestations based on most of the evidence. HCV: Hepatitis C virus; SVR: Sustained virologic response.

mitochondrial β-oxidation and thus lipid degradation, and reduces apolipoprotein exportation, in particular very low-density lipoprotein cholesterol (LDL), resulting in significant intracellular lipid accumulation and circulating hypocholesterolemia and hypolipoproteinemia[13].

Several studies have linked successful HCV eradication with rebound rise in lipid levels. Meissner et al[24], who investigated the influence of DAAs, sofosbuvir and ribavirin, on serum lipid profiles and intrahepatic lipid-related genes expression in patients with genotype 1 CHC, reported that serum LDL level and molecular size increased early in therapy, whereas triglycerides concentration and very low-density lipoprotein cholesterol (VLDL) particle size decreased concomitantly, irrespective of treatment outcome. This observation likely reflects a direct effect on lipid metabolism associated with the inhibition of HCV replication[24]. This notion was further supported in several reports. Clark et al[25], used cholesterol metabolites as an indicator to evaluate the impact of HCV on lipid metabolism. In this study, genotype 3 but not genotype 2 showed a selected interference with late cholesterol synthesis pathway, resulting in hypocholesterolemia. However, this interference was resolved after SVR. Another Japanese study that included 100 subjects showed early rebound (within 28 d) in LDL level in CHC patients who underwent interferon-free DAA treatment. However, the elevation was regimen-specific, more prominent in the group who received daclatasvir and asunaprevir for 24 wk than in those received ledipasvir and sofosbuvir for 12 wk[26]. In addition, many reports correlated the rebound in lipid profile with treatment response status[27-29]. This was clearly demonstrated by Corey et al[18], which conducted a 2 steps study to evaluate the relationship between HCV infection and its treatment with lipid levels. After confirming that HCV infection is associated with significantly lower LDL concentrations in the first step, they found that remarkable hyperlipidemia was developed in patients who achieved viral clearance, compared to non-responders or those who relapsed. In the same context, some studies have further investigated the role HCV genotype on post-SVR hypercholesterolemia. In a study that included 215 patients, Fernández-Rodríguez et al[28] observed that increased serum cholesterol levels were associated with genotype 3 in patients who achieved SVR. In contrast, un-changed serum cholesterol figures were noted in genotype 3 non-responders and genotype 1 regardless of response[28]. Although the reversal of both hepatic steatosis and hypolipidemia has been reported only in genotype 3 in this study, there is accumulating evidence demonstrating that the reversal of hypolipidemia is not HCV-genotype specific[29,30].
Many reports proposed that atherosclerotic CVD risk increases after successful eradication of HCV due to the unfavorable lipid profile, which is a result of reversed hypolipidemia, represented in high serum LDL and small dense LDL. The latter has greater atherogenic potential and is a better marker for prediction of CVD than LDL[31,32]. The important question at this point is whether these patients require lipid-lowering treatment. According to the National Cholesterol Education Program Adult Treatment Plan Guideline III, patients should be put on lipid lowering agents for: (1) an LDL >100 mg/dL, if they have coronary heart disease or its equivalents[1]; (2) an LDL >130 mg/dL, if they have two or more major coronary heart disease risk factors[2]; and (3) an LDL >190 mg/dL, with none or one major risk factor[33]. Corey and his colleagues have found that 13% of their studied cohort had post-SVR LDL levels requiring lipid lowering therapy as these patients had values > 130 mg/dL plus presence of two or more major coronary heart disease risk factors. Nonetheless, before antiviral therapy, none of these patients had LDL readings requiring medications. Post-treatment lipid profile deterioration may reach clinically meaningful level requiring the consideration for cholesterol lowering therapy.

HEPATIC STEATOSIS

Hepatic steatosis is a frequent histological liver finding in patients with CHC[34]. Since HCV is known to hijack lipid metabolic pathways for virion maturation and secretion, several possible mechanisms of HCV-induced liver steatosis have been suggested. HCV induces lipogenesis by increasing intrahepatic fat milieu through sterol regulatory element binding protein 1c, which is a protein that overexpresses LDL receptors which in turn facilitates fatty acid uptake by hepatocytes, leading to higher intrahepatic fat content[35]. In contrast, HCV inhibits lipolysis by disturbing mitochondrial β-oxidation[36], either directly by the virus itself or indirectly via downregulation of the enzyme carnitine palmitoyltransferase-1, which regulates fatty acids oxidation[37,38]. These two mechanisms further potentiated by HCV-induced IR[39]. Moreover, HCV core protein suppresses the activity of microsomal triacylglycerol transfer protein, which is used for the assembly and secretion of VLDL, resulting in increased intracytoplasmic lipid droplets and therefore steatosis[40]. Miyoshi et al[41], who studied the role of HCV core protein in development of steatosis in HCV genotype 2, revealed that core protein activates the enzyme δ-9 desaturase, fatty acid metabolizing enzyme, and therefore leads to accumulation of triglycerides. This lipid metabolism disorder was also associated with mitochondrial dysfunction[41].

Hepatic steatosis is commonly reported among patients with HCV genotype 1 and genotype 3. Its occurrence in the latter has been correlated mainly to the previously mentioned mechanisms. Therefore, resolution of steatosis observed after successful viral eradication suggests a direct steatogenic pathway for HCV genotype 3[42]. This hypothesis was backed in a study of patients treated with interferon-based regimen, in which 91% of genotype 3 patients and only 43% of other genotypes have had their steatosis improved after viral cure[43]. Kumar et al[44], have also observed similar findings when steatosis was profoundly reduced in genotype 3 patients post-SVR, while no change irrespective of the treatment response occurred in genotype 1. Although development of fatty liver was associated with viral characteristics in genotype 3 (viral steatosis), the condition in genotype 1 corresponded to metabolic features such as glucose level and IR (metabolic steatosis). This observation suggests that in patients with genotype 1, factors other than the viral features play an essential role in the development of hepatic steatosis[28].

After achieving SVR with antiviral therapy, reversal of steatosis is the most common reported outcome, which was seen in several studies[17,27,28,39]. However, recent reviews showed contradictory findings[45,46]. In a prospective study that investigated the prevalence of hepatic steatosis and fibrosis in patients with CHC post-SVR, steatosis prevalence found to be 47.5%, almost as same as the pre-treatment figure (50%). Besides, overall average fibrosis score was reduced after viral clearance. Nevertheless, patients who had steatosis have maintained clinically significant fibrosis scores, compared to those without fatty liver[46]. In another study included 49 patients aimed to evaluate the impact of DAAs on glucose and lipid homeostasis, controlled attenuation parameter values were markedly increased at the end of follow up compared to baseline. More importantly, this finding was independent of weight gain, since no change in body mass index (BMI) was observed over time[45].
Patients with CHC and viral-induced hepatic steatosis have been shown to have worse hepatic outcomes in pre-treatment setting[47]. Nonetheless, a recent study depicts that presence of post-SVR steatosis does not carry a better risk profile[48]. In this study, which aimed to assess the effect of steatosis on HCC and all-cause mortality in CHC patients post-SVR, presence of fatty liver was associated with a considerable 7.5-fold increase in both primary endpoints[48]. Furthermore, there is also a substantially higher risk of EHMs, particularly CVD, after amelioration of steatosis post-SVR[17]. These findings combined highlight the importance of hepatic steatosis as a major risk factor for poor outcome and warrant a special consideration of screening and follow-up in this population.

INSULIN RESISTANCE & DIABETES MELLITUS

Based on multiple epidemiological studies, metabolic alterations such as IR, DM, and metabolic syndrome are frequent comorbidities in patients with CHC, as opposed to controls[19,49]. The rationale behind this association is still not completely understood but it could be attributed to the presence of liver disease, metabolic characteristics such as obesity, or the inflammatory process induced by HCV infection. HCV has been found to modulate insulin signaling pathways although the precise molecular mechanism of HCV-mediated IR is not fully understood. In two mouse-model experimental studies, HCV core protein was found to play a major role in the development of IR[50,51] particularly through PA28γ gene-dependent pathway[50]. HCV genotypes 1, 2 and 4[52] and genotypes 1 and 4[53] were noticed to have higher IR compared to genotype 3[52] and genotypes 2 and 3[53], respectively. Oxidative stress and proinflammatory cytokines were also found to play a role in de novo IR[54,55]. The disruption in glucose and lipid metabolism associated with IR[56] leads to evolution of hepatic steatosis and development of DM. Among subjects with chronic liver disease, the prevalence of DM in CHC patients prior to treatment varies from 13.6% to 67.4%, which is higher than that reported in individuals with other etiologies, such as chronic hepatitis B[57]. Furthermore, a case-control study demonstrated that the presence of CHC was associated with an over 11-fold increase in risk of developing DM over a follow-up period of 9 years[58]. DM seems to have a bidirectional relationship with HCV, in which the latter causes IR while DM is linked with more aggressive course of HCV-related outcomes such as progressive fibrosis[49,59,60], and increased risk of cirrhosis and HCC[61,62]. All the above conditions make patients with CHC more susceptible to have metabolic syndrome[63]. However, due to the hypolipidemia caused by HCV infection[64], which does not fit the traditional diagnostic criteria, a peculiar type of metabolic syndrome known as hepatitis C-associated dysmetabolic syndrome has been defined[65].

There is frequent evidence that have showed a beneficial effect of antiviral therapy using interferon-based regimens on IR in long-term HCV responders. Thompson et al[66], who studied 1038 non-diabetic patients, concluded that IR was substantially decreased in HCV-genotype 1 responders but not in genotype 1 non-responders or those with genotype 2 or 3 irrespective of treatment outcome. This finding was independent of any changes in BMI. Similar findings were also reported in a prospective study[29]. In the Virahep-C, a prospective multicenter study, an improvement in the homeostatic model assessment for IR (HOMA-IR) was observed 24 wk after treatment completion among HCV genotype 1 patients who had IR prior to therapy[57]. Nonetheless, Aghemo et al[68], who enrolled 384 non-diabetic patients with HCV genotypes 1 and 4 failed to display any differences in HOMA-IR values between baseline and 24 wk post-SVR. All the above findings indicate that longer follow-up may be needed to better assess glucose metabolism disturbances after HCV viral clearance with interferon-based regimens, especially in HCV genotype 1 patients. Paradoxically, in a head-to-head comparison of 178 subjects with HCV genotype 1 and 4 between interferon-based antiviral therapy and DAAs to assess metabolic outcomes, there was a significant elevation in HOMA-IR in those who have taken interferon-based regimen[31].

In addition to its effect on IR, antiviral therapy has been thought to decrease incidence of post-SVR hyperglycemia and DM. Interferon-based regimens have been studied extensively and they are usually associated with a decreased incidence of DM in non-diabetic patients with CHC after elimination of HCV[69]. However, several studies have emphasized the beneficial role of attaining SVR, which lessens glucose metabolism abnormalities induced by HCV infection[10,39,70]. Other studies could not detect any significant differences between treatment responders and non-
responders[71,72]. Despite these conflicting results, a meta-analysis that included seven studies aiming to investigate the correlation between HCV clearance via interferon-based regimens and the incidence of hyperglycemia demonstrated that SVR is associated with lower risk of hyperglycemia (odds ratio 0.49, 95% confidence interval (CI): 0.42-0.58). Heterogeneity between studies was minimal, indicating a reliable result. On the other hand, the use of DAAs for viral eradication was not investigated thoroughly. Studies on incidence of DM in non-diabetic patients demonstrated less glucose disturbance in long-term responders[10,73]. In a retrospective study conducted in United States, 5127 non-diabetic subjects with HCV were enrolled to investigate how the response to HCV treatment impacted the risk of subsequent DM. The authors found that those who achieved SVR had markedly lower risk of developing DM, compared to those with treatment failure[10]. Two studies investigated the effect of DAAs on previously known diabetic patients[74,75]. One illustrated an improvement in glycemic status after viral cure while in the other there was no difference in glycosylated hemoglobin between pretreatment and post-treatment values. Importantly, one-third of patients in the latter study required escalation of anti-diabetic therapy during antiviral treatment. Further long-term prospective studies are still needed to resolve the current dilemma of changes on IR related to antiviral treatment.

CARdiovascular disease

HCV infection has been linked to an array of EHMs, including an increased risk of CVD[76-79]. Several direct and indirect HCV pro-atherogenic mechanisms have been postulated. HCV is assumed to play a direct role in the development of arterial atherosclerosis by inducing endothelial dysfunction, likely through interleukin 18[80], a pro-inflammatory cytokine. Likewise, it has been observed that HCV has the ability to live and replicate inside carotid plaques[81], which further supports an immediate pro-atherogenic effect. Moreover, chronic inflammation and oxidative stress that are caused by structural and non-structural viral proteins have also been shown to trigger plaque formation[80]. In a multicenter Italian study that evaluated the effect of attaining SVR using DAAs on subclinical carotid arteriosclerosis compared to an untreated cohort, ultrasonographic carotid measurements showed a significant reduction in mean carotid intima-media thickness in treatment group at the end of follow-up compared to baseline (from 0.94 mm to 0.81 mm, P < 0.001). No significant changes in the intima-media thickness were found in the control group. The BMI of these patients did not change during follow-up, while a significant increase in serum cholesterol levels was observed. The study concluded that eradication of HCV by DAAs led to an amelioration in carotid atherosclerosis, particularly intima-media thickness. Furthermore, HCV can also induce atherosclerosis indirectly since it is associated with an increased risk of metabolic syndrome components, including IR, DM, and hepatic steatosis, which are well-known predisposing factors for CVD[82-84]. On the other hand, some studies have failed to show any significant association between HCV and cardiovascular events[85,86].

Several studies have shown that either antiviral therapy or the attainment of SVR minimize CVD risk[87-90]. However, the results are rather controversial. Butt et al[87], who studied the effect of antiviral therapy, interferon- or DAAs-based regimens, on CVD risk found that the incidence of CVD in treatment arm was 7.2% in comparison with 13% in control group, regardless of the antiviral regimen. Treatment with DAAs was superior to interferon-based regimen, with a hazard ratio (HR) of 0.57 (95% CI: 0.51-0.65) and HR 0.78 (95% CI: 0.71-0.85), respectively. SVR was also associated with lower risk of incident CVD events HR 0.87 (95% CI: 0.77-0.98). In a nation-wide cohort study on Taiwanese residents with HCV who had received interferon-based regimens compared to an untreated cohort, antiviral therapy was associated with lower risks of acute coronary syndrome and ischemic stroke, with HR 0.77 (95% CI: 0.62-0.97) and HR 0.62 (95% CI: 0.46-0.83), respectively. This risk reduction was not observed in subject who had insufficient treatment course (< 16 wk)[88]. Further supporting data was observed in a study comprising 3385 HCV patients, which found that SVR was associated with a lower relative hazard reduction and absolute risk reduction for CVD[89]. However, some epidemiological studies have found contradictory findings. A large retrospective cohort study which enrolled 160875 subjects was aimed to investigate the impact of successful viral eradication on a variety of EHMs. In terms of CVD risk, the study concluded that SVR was associated with a diminished risk for stroke HR 0.84 (95% CI: 0.74-0.94), but not for CVD aHR 1.12 (95% CI: 0.81-1.56), when
compared to the untreated cohort\cite{69}. From the same perspective, a negative result was also reported by Leone et al\cite{72}, who studied the influence of SVR on EHM. The researchers did not find any significant cardiovascular risk reduction in SVR group compared to non-SVR, with HR 1.14 (95\% CI: 0.57-2.3). Despite disparities in the findings across individual studies, a meta-analysis demonstrated that SVR significantly reduces CVD risk, with a pooled of HR 0.76 (95\% CI: 0.61-0.94)\cite{31}.

Apart from the direct treatment effect on CVD risk, therapeutic changes on other EHM may also play role in the development of atherosclerotic events. Deteriorated lipid profile after HCV clearance has been shown to predispose patients to an elevated risk of CVD\cite{31}. In a study of 617 patients with a mean follow-up of 26.8 mo, Huang et al\cite{31} investigated whether deterioration of lipid profile post-SVR increased the risk of cardio-cerebral disease. Five patients developed cardio-cerebrovascular events (3 CVD and 2 cerebrovascular disease) over 1376 person-years. An LDL surge >40\% was found to be the only predictor of these vascular events, with a HR of 15.44 (95\%CI: 1.73-138.20)\cite{31}. Evidence on risk of CVD in CHC pre- or post-treatment remains contro-versial. Nonetheless, most of the literature indicates that achieving SVR via antiviral therapy is associated with a significant risk reduction.

**CONCLUSION**

EHM including cardiometabolic conditions are commonly seen among patients with CHC infection. Data on these conditions after elimination of HCV is inconsistent. However, the predominant evidence in the literature suggests that viral clearance using antiviral therapy leads to deterioration in lipid profile, reduction in the incidence of metabolic alteration such as IR, DM, and hepatic steatosis, and improvement in CVD risk. To determine more robust level of association between SVR and EHM and to understand the exact mechanisms of how antiviral therapies act on these EHMs, large prospective studies with long-term follow-up are needed.

**REFERENCES**


Negro F. HCV infection and metabolic syndrome: which is the chicken and which is the egg? Gastroenterology 2012; 142: 1288-1292 [PMID: 22537435 DOI: 10.1053/j.gastro.2011.12.063].


Cardiometabolic complications


